Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications.

COVID-19 SARS-CoV-2 coronavirus disease respiratory infections serologic assays severe acute respiratory syndrome coronavirus 2 vaccine-preventable diseases viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
03 2022
Historique:
entrez: 24 2 2022
pubmed: 25 2 2022
medline: 3 3 2022
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys can estimate cumulative incidence for monitoring epidemics, requiring assessment of serologic assays to inform testing algorithm development and interpretation of results. We conducted a multilaboratory evaluation of 21 commercial high-throughput SARS-CoV-2 serologic assays using blinded panels of 1,000 highly characterized specimens. Assays demonstrated a range of sensitivities (96%-63%), specificities (99%-96%), and precision (intraclass correlation coefficient 0.55-0.99). Durability of antibody detection was dependent on antigen and immunoglobulin targets; antispike and total Ig assays demonstrated more stable longitudinal reactivity than antinucleocapsid and IgG assays. Assays with high sensitivity, specificity, and durable antibody detection are ideal for serosurveillance, but assays demonstrating waning reactivity are appropriate for other applications, including correlation with neutralizing activity and detection of anamnestic boosting by reinfections. Assay performance must be evaluated in context of intended use, particularly in the context of widespread vaccination and circulation of SARS-CoV-2 variants.

Identifiants

pubmed: 35202525
doi: 10.3201/eid2803.211885
pmc: PMC8888213
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

672-683

Références

Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Epidemiology. 2021 Jul 1;32(4):518-524
pubmed: 33935138
Open Forum Infect Dis. 2020 Nov 17;8(1):ofaa555
pubmed: 33442555
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33361342
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261718
Diagn Microbiol Infect Dis. 2021 Jun;100(2):115340
pubmed: 33596485
Lancet. 2020 Oct 24;396(10259):1335-1344
pubmed: 32987007
Sci Adv. 2021 Jul 30;7(31):
pubmed: 34330709
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
PLoS One. 2019 Jul 22;14(7):e0219854
pubmed: 31329615
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Lancet Glob Health. 2021 Jun;9(6):e773-e781
pubmed: 33711262
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Transfusion. 2021 Sep;61(9):2677-2687
pubmed: 34121205
Transfusion. 2021 Apr;61(4):1160-1170
pubmed: 33554362
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Immunity. 2020 Dec 15;53(6):1272-1280.e5
pubmed: 33242394
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Int J Environ Res Public Health. 2021 Jun 11;18(12):
pubmed: 34208212
Clin Infect Dis. 2021 Nov 2;73(9):e3066-e3073
pubmed: 33147319
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
Clin Infect Dis. 2021 Nov 2;73(9):e2853-e2860
pubmed: 33011792
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH